AI assistant
Sending…
MiNK Therapeutics, Inc. — Director's Dealing 2021
Oct 21, 2021
34471_dirs_2021-10-20_e84810cc-a0bb-41d9-8a94-28bb548a4201.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2021-10-13
Reporting Person: WIINBERG ULF (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 278300 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.02 | 2028-11-19 | Common Stock (27830) | Direct | |
| Stock Option (Right to Buy) | $0.01 | 2030-01-30 | Common Stock (111320) | Direct | |
| Stock Option (Right to Buy) | $3.03 | 2031-02-11 | Common Stock (20872) | Direct |
Footnotes
F1: Represents an option to purchase shares of the common stock, which vests in three equal annual installments beginning on November 19, 2019.
F2: Represents an option to purchase shares of our common stock, which vested as to 33% of the underlying shares on January 30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.
F3: Represents an option to purchase shares of the common stock, which vests fully on February 11, 2022.
More from MiNK Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Earnings Release
2026
May 15
Annual Report
2026
Mar 31
Earnings Release
2026
Mar 31
Regulatory Filings
2026
Mar 27
Board/Management Information
2026
Mar 19
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Jan 14
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6